Nimotuzumab in Children With HGG

Status Completed

Clinical Trial Summary

Determination of efficiency of nimotuzumab in children with high grade glioma.

Clinical Trial Description

High grade malignant gliomas are tumors grade III and IV according to WHO classification, that originate from oligodendroglia and astrocytes, where the latter are also known as anaplastic astrocytoma(WHO grade III) and glioblastoma(WHO grade IV). This also includes intrinsic pontine gliomas of adolescents, which are usually not documented histologically due to their localisation, but they have a similar clinical progress when compared to high grade malignant astrocytic tumors. Among various molecular alterations, malignant gliomas overexpress EGFR (epidermal growth factor) in nearly 50% of cases, which is particularly pronounced in glioblastoma.(Schlegel 2003) Standard therapy consists of radical surgery as extensive as medically responsible followed by radiotherapy dose of 60 Gy, which is aimed at the area with a safety margin. The long-term efficacy of additional chemotherapy has been a subject for controversy for several decades. The combination of all three treatment modalities in grade III tumors can lead to median survival times of 3-5 years in adults.

For this treatment group reports of 5 year recurrence free periods in 33-50% of cases have been reported in children and adolescents.

For glioblastoma(WHO grade IV) 5year recurrence free periods are 3% in elderly patients and 10-20% for adolescents.(Schlegel 2003) In German speaking territories chemotherapy with Cisplatin, Etoposid and Ifosfamid is used as a postoperative treatment option for adolescents and this disease.(Wolff HIT-GBM) In case of recurrence therapy choices are even more limited, thus if medically feasible the enrolment in clinical trials is an option.

In this study the aim is to use an antibody directed against the EGF-receptor to effect the proliferation of the tumor cells negatively. Pilot studies conducted in adults indicate that the median survival time for patients with malignant glioma can be prolonged by the antibody treatment. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00561873
Study type	Observational
Source	Oncoscience AG
Contact
Status	Completed
Phase	N/A
Start date	June 2004
Completion date	February 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05023551` - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma	Early Phase 1
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Active, not recruiting	`NCT02655601` - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001	Phase 2
Terminated	`NCT03690869` - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	Phase 1/Phase 2
Completed	`NCT01466686` - Low Dose Radiation Therapy for Glioblastoma Multiforme	Phase 2
Recruiting	`NCT05212272` - MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Recruiting	`NCT05925218` - Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Active, not recruiting	`NCT04911621` - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1/Phase 2
Not yet recruiting	`NCT06333899` - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Early Phase 1
Recruiting	`NCT04734444` - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue	N/A
Completed	`NCT03775369` - Glioma and Exercising	N/A
Completed	`NCT02022644` - Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma	Phase 1
Completed	`NCT00780819` - Borderzone Sampling	N/A
Recruiting	`NCT06072586` - Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions	Early Phase 1
Completed	`NCT01390948` - A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma	Phase 2
Recruiting	`NCT03952598` - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	N/A
Recruiting	`NCT05630664` - Liquid Biopsy in High-grade Gliomas and Meningiomas
Recruiting	`NCT05298995` - GD2-CAR T Cells for Pediatric Brain Tumours	Phase 1
Completed	`NCT01222754` - Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT05278208` - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.